PETRI DISH PERSPECTIVES

Send us Fan MailAfter a two-generation family history of heart disease, Dr. Meesha Dogan set out to change how the disease is detected. As founder and CEO of Cardio Diagnostics, she built and commercialized what the company describes as the first epigenetics-based clinical test for heart disease driven by AI, then took the company public on Nasdaq in 2022. Since then, it has earned a dedicated AMA CPT code for its PrecisionCHD test, won a Vizient innovative technology contract, and launched its first international partnership in India.In this episode, Dr. Dogan unpacks why roughly 80% of cardiovascular events are preventable yet still so often missed, how combining genetics and epigenetics gives a fuller picture of heart disease risk, and what it takes to move a diagnostic from the lab to reimbursement, health systems, and employers.Check out Cardio Diagnostics: https://www.cdio.ai/🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #Cardiology #HeartHealth #Epigenetics #AIinHealthcare #PrecisionMedicine #Diagnostics #Biotech #HealthTech #PreventiveMedicine #WomenInSTEM #CardioDiagnosticsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026!This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled the GLP-1 race, and M&A activity that shows Big Pharma is quietly pivoting away from oncology toward rare disease, pain, and RNA therapeutics. The FDA approved dostarlimab in locally advanced rectal cancer, tucatinib in HER2-positive breast cancer, and talazoparib plus enzalutamide in metastatic prostate cancer — three meaningful wins for patients in a single month. Lilly’s retatrutide beat Ozempic head-to-head with 20.9% weight loss in diabetic patients, cementing its status as the next major GLP-1 contender. On the deal front, Shionogi paid $2 billion for IntraBio in rare neurodegeneration, Viatris acquired Pacira BioSciences for $1.65 billion in non-opioid pain, and Merck KGaA bought Silence Therapeutics at a 130% premium — six deals totaling over $7 billion for the month. VC finished strong with Formation Bio raising $600 million to buy drug candidates and Dren Bio closing $350 million, part of over $1.4 billion in rounds in the final week alone. And HHS greenlighted six experimental peptides over the open objections of FDA career scientists — a regulatory move that signals growing tension between evidence standards and the current policy posture. The bigger story: capital is flowing, but it’s getting selective — and the therapeutic areas winning M&A attention this month tell you exactly where the smart money thinks the next decade of returns will come from.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we explore Endeavor Health, the Chicago-area hospital system most Illinoisans have driven past but couldn’t name. Born from Evanston Hospital in 1891, grown into NorthShore University HealthSystem, expanded through a 2022 merger with Edward-Elmhurst Health, and rebranded as Endeavor Health in December 2023, this is a system that has been quietly becoming one of the largest in the state.We break down Endeavor’s origins, its nine-hospital suburban footprint, the NorthShore Research Institute, and the financial reality of running a $6.4 billion system at near-zero operating margin and why that made what happened next almost inevitable.On October 14th, 2026, Endeavor and Rush University System for Health announced a proposed merger that would create a $10 billion combined system with 12 hospitals, 400+ care sites, 46,000 employees and clinicians, and over 2 million patients a year. We get into the deal mechanics, the leadership shake-up, the $1 billion endowment investment, and what nurses, patients, and healthcare economists are already pushing back on.This is a story about scale, survival, and what happens when a fragmented market finally stops pretending consolidation isn’t coming.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #EndeavorHealth #Rush #ChicagoHealthcare #HospitalMerger #HealthcareConsolidation #NorthShore #EdwardElmhurst #RushUniversity #HealthPolicy #HealthcareNews #LifeSciences #Healthcare #HealthcareLeadership #BiotechNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailAfter years of building discovery engines inside diagnostics, Kristin Gleitsman has become one of the more skeptical voices in AI and biology. A Caltech chemistry PhD, Kristin built Veracyte’s Discovery Research function from the ground up and helped shape the strategy behind its acquisition of C2i Genomics. Now, as Chief Science Officer of Eigen Bio, the focus is on a harder question than building bigger models: what has an AI model actually earned the right to claim?In this episode, Kristin unpacks why more data layers don’t automatically mean more biological truth, how better mechanistic evidence could change drug development decisions, and what it takes to hold AI-bio claims, including your own company’s, to a higher standard. Kristin also shares lessons from the weekly AI∩Bio newsletter on separating real progress from hype.Check out Eigen Bio: https://eigenbioai.com/Read AI∩Bio: Reading the Revolution: https://kristinrulegleitsman.com/ai-∩-bio/🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #AIinBiotech #DrugDiscovery #PrecisionMedicine #Diagnostics #Multiomics #Biotech #HealthTech #Oncology #AIBio #EigenBioSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With mutations present in roughly 30% of all new cancer diagnoses, including pancreatic, lung, and colorectal cancers, RAS has long been considered undruggable. Revolution bet their entire company on proving that wrong.We break down the science behind their tricomplex inhibitor platform, the three lead drugs in their pipeline, daraxonrasib, elironrasib, and zoldonrasib, and the landmark Phase 3 RASolute 302 results that showed unprecedented overall survival in metastatic pancreatic cancer, earned a Plenary presentation at ASCO 2026, and triggered an FDA NDA review.But this is also a story about the pressure of building an ambitious company with no revenue, nearly $1 billion in annual R&D spend, and a failed $30 billion acquisition attempt with Merck that sent the stock crashing 26% in a single day. Revolution walked away from the deal. The question now is whether that confidence was prescient or premature.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #RevolutionMedicines #RAS #KRAS #Oncology #PancreaticCancer #LungCancer #Daraxonrasib #Biotech #DrugDiscovery #PrecisionOncology #CancerResearch #FDA #LifeSciences #Healthcare #BiotechTok #BiotechNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailAfter training as a physician, earning an MBA from Wharton, and co-founding Sonara Health, a digital health company that raised over $10 million from the NIH, VCs, Dr. Avinash Jayaraman could have gone in almost any direction. He chose to focus on one of the most urgent and underserved crises in adolescent health: the mental health epidemic driven by technology overuse.In this episode, Dr. Jayaraman unpacks why screen time and social media have become a clinical problem, not just a parenting debate, what it actually takes to build a mental health startup for kids and teens in a system that has historically ignored them, and why he believes the solution has to combine real clinical care with a deep understanding of how technology rewires the adolescent brain.Check out Blue Light Health: https://bluelighthealth.com/🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BlueLightHealth #MentalHealth #AdolescentHealth #DigitalHealth #TechAddiction #ScreenTime #HealthTech #Startups #Healthcare #BiotechTokSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailWelcome to your essential overview of the global biotech and pharmaceutical landscape for September 2026!This month was defined by blockbuster dealmaking, historic FDA approvals, and a growing recognition that pharmaceutical innovation is shifting east. AstraZeneca made a $2 billion strategic bet on Summit Therapeutics and its ivonescimab program, Novo Nordisk paid up to $2.6 billion for a once-weekly oral GLP-1 from China's Hengrui, and Eli Lilly continued its relentless dealmaking streak with a $3.25 billion InnoCare partnership. On the regulatory front, the FDA approved the first-ever treatment for Sanfilippo syndrome, a first-in-class Parkinson's drug, the world's first radioligand equivalent, and a new once-weekly insulin, a remarkable month for patients with rare and chronic diseases. ADARx raised $446 million in one of biotech's largest IPOs of the year, and Electra Therapeutics upsized its own raise to $350 million, signaling that the IPO window remains open for the right science. Meanwhile, Novo's total workforce cuts reached 13,000 and BMS continued trimming headcount, a reminder that even the industry's biggest players are restructuring for what comes next. The bigger story is unmistakable: China is no longer just manufacturing drugs for the West, it is discovering them, and the deals signed this month prove that Big Pharma has fully accepted that reality.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #BiotechNews #PharmaNewsSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we explore Jiangsu Hengrui Pharmaceuticals, the Chinese pharma giant that started as a state-owned generic drug factory in 1970 and quietly became one of the most important drug companies in the world. Over $15 billion in deals with GSK and Novo Nordisk. The world's top clinical trial sponsor. One of the top five drug pipelines globally. All from a city most people can't find on a map.We break down how Hengrui made the pivot from generics to innovation, why Western pharma is now writing billion-dollar checks for Chinese science, and the controversies, including a scathing FDA warning letter and corruption scandals, that complicate the story.Because Hengrui wasn't hiding. It was building, the whole time.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #Hengrui #ChinaBiotech #Pharma #Biotech #DrugDiscovery #NovoNordisk #GSK #GLP1 #Oncology #LifeSciences #Healthcare #BiotechInnovation #PharmaceuticalIndustrySupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailAfter years of running a school on the rigid rhythm of bells, Dr. John Murphy walked away from K-12 education and into something he never trained for: performing history at bars.In this episode, John unpacks how a credentialed academic builds an audience outside the walls of a traditional institution, why humor and analogies are the secret weapons of great storytelling, and what it actually takes to turn expertise into something people will pay a bar tab to hear. Quick note: this one's a bit of a departure from our usual biotech and pharma coverage, but the story was too good to pass up.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!https://linktr.ee/maneadkhin#PetriDishPerspectives #Edutainment #ScienceCommunication #ContentCreator #PersonalBrand #PublicSpeaking #HistoryLecture #Storytelling #ChicagoEvents #CreatorEconomySupport the show© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan MailIn this episode of Petri Dish Perspectives, we explore Anew Labs, the AI drug discovery company that emerged from one of the most unexpected places in biotech: ByteDance, the parent company of TikTok. Fresh off a $290 million raise at a $1.5 billion valuation, Anew is betting that artificial intelligence can fundamentally change how we discover medicines, not by making existing drug development slightly faster, but by rethinking the entire discovery process from the ground up.We'll break down why ByteDance got into drug discovery in the first place, how Anew's AI platforms work across protein structure prediction, molecular design, and antibody optimization, and what makes its first-in-class small molecule IL-17 program one of the most scientifically ambitious bets in the company's pipeline. We'll also explore the broader competitive landscape, from Anthropic's $400 million acquisition of Coefficient Bio to NVIDIA and Eli Lilly's $1 billion co-innovation lab and what it means that Big Tech is no longer just building tools for pharma, but trying to become the drug company itself.But the biggest question hanging over all of it remains unanswered: can AI actually discover drugs? Not molecules that look promising on a computer. A medicine that works in humans, survives clinical development, gets approved, and changes patient outcomes. We'll dig into why the proof hasn't arrived yet and why Anew is one of the most important tests of that question in the world right now.Because the next breakthrough in medicine may not come from a traditional pharmaceutical company. It may come from an algorithm trained on biology and a team willing to bet everything that the computer got it right.🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!https://linktr.ee/maneadkhin#PetriDishPerspectives #AnewLabs #AIDrugDiscovery #ByteDance #Biotech #Biotechnology #Pharma #ArtificialIntelligence #DrugDiscovery #MachineLearning #LifeSciences #Healthcare #Isomorphic #Anthropic #NVIDIA #EliLilly #BispecificAntibody #Immunology #AIinHealthcare #BiotechInnovation #PrecisionMedicine #DrugDevelopmentSupport the show© 2026 The Perspective Bureau LLC. All rights reserved.